Summit Therapeutics up 7.75% on positive Phase 3 ivosidenib data in cholangiocarcinoma

SMMT Summit Therapeutics Inc

$17.31 +0.23%

View chart & analysis →

1. 1Summit Therapeutics (SMMT) rises 7.75% on positive top-line Phase 3 data for partner Akeso's ivosidenib in advanced cholangiocarcinoma
2. 2In HARMONi-GI1, ivosidenib plus chemotherapy demonstrated statistically significant overall survival superiority versus durvalumab plus chemotherapy
3. 3As first-line treatment in 682 Chinese patients, it also met the key secondary endpoint; not yet approved in the U.S. or Europe, with detailed results to be presented at a conference

Source InvestorsHub +1 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →